Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Artemether

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Artemether
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Artemisinin and derivatives, plain
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BE02; WHO ATC P01BE05

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Artemether, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis22.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Artemether in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Artemether with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.

    NCT00386763 · start 2006-08

    Registered record
    Registry ID
    NCT00386763
    Conditions
    Malaria; Falciparum
    Interventions
    Artemether-lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-08
    Completion
    2007-03
    Enrolment
    890

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Falciparum
    InterventionArtemether-lumefantrine
    PhasePhase 3
    Registry statusCompleted

  • ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria

    NCT00316329 · start 2006-03

    Registered record
    Registry ID
    NCT00316329
    Conditions
    Malaria
    Interventions
    Artesunate + Amodiaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-03
    Completion
    Not recorded
    Enrolment
    1,032

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionArtesunate + Amodiaquine
    PhasePhase 3
    Registry statusCompleted

  • Amodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children

    NCT00406146 · start 2004-10

    Registered record
    Registry ID
    NCT00406146
    Conditions
    Uncomplicated Malaria
    Interventions
    amodiaquine+artesunate/artemether-lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2004-10
    Completion
    2006-12
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Malaria
    Interventionamodiaquine+artesunate/artemether-lumefantrine
    PhasePhase 3
    Registry statusUnknown

  • Lapdap and Coartemether for Uncomplicated Malaria

    NCT00118794 · start 2004-09

    Registered record
    Registry ID
    NCT00118794
    Conditions
    Malaria
    Interventions
    Chlorproguanil-dapsone (Lapdap); Lumefantrine-artemether (Coartemether )
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-09
    Completion
    2005-06
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionChlorproguanil-dapsone (Lapdap); Lumefantrine-artemether (Coartemether )
    PhasePhase 3
    Registry statusCompleted

  • Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status

    NCT00304980 · start 2003-03

    Registered record
    Registry ID
    NCT00304980
    Conditions
    Plasmodium Falciparum Malaria
    Interventions
    ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2003-03
    Completion
    2005-04
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum Malaria
    InterventionARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE
    PhaseNot applicable
    Registry statusTerminated